ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Short Interest Update

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) saw a significant decline in short interest in November. As of November 15th, there was short interest totalling 28,900 shares, a decline of 36.5% from the October 31st total of 45,500 shares. Approximately 2.7% of the company’s stock are short sold. Based on an average trading volume of 1,220,000 shares, the short-interest ratio is presently 0.0 days.

ZyVersa Therapeutics Stock Performance

ZyVersa Therapeutics stock opened at $1.07 on Thursday. ZyVersa Therapeutics has a 1-year low of $1.03 and a 1-year high of $42.39. The firm’s fifty day simple moving average is $1.93 and its 200-day simple moving average is $3.14.

About ZyVersa Therapeutics

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.